11 June 2019

TauRx recognized as a Technology Innovation leader in the neurodegenerative disease management industry

ABERDEEN, Scotland and Singapore, 11 June 2019 – TauRx, a leader in neurodegenerative disease research, today announced that it is the recipient of Frost & Sullivan’s 2019 Asia Pacific Neurodegenerative Disease Management Technology Innovation Award.

Read more here.

TauRx recognized as Technology Innovation leader

– TauRx, a leader in neurodegenerative disease research, today announced that it is the recipient of Frost & Sullivan’s 2019 Award

Older Press Releases

More news

MHRA confirms acceptance of UK Marketing Authorisation Application for HMTM

TauRx submits UK marketing authorisation application for HMTM as a treatment for Alzheimer’s disease

Doctor examining MRI, MRT, CT scan image of human brain. Medical treatment concept. Diagnosis of the disease humans head. Close up.

Two year sustained cognitive benefits of Hydromethylthionine Mesylate (HMTM) indicated by TauRx’s LUCIDITY trial

Further reading

For decades, Professor Claude Wischik, co-founder and CEO of TauRx, has led a scientific research team dedicated to finding an effective treatment for neurodegenerative diseases.

Doctor or nurse caregiver with senior couple at home or nursing home

Clinical trials

TauRx recently completed its latest Phase III clinical trials in Alzheimer’s disease and in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD).

Gears. Cog mechanism, engine system, operation progress, gear shift, industry innovation, engineering solution, technology concept.

Environmental, Social and Governance at TauRx

Maintaining integrity, accountability and transparency in our pursuit of life-changing treatments